CTLA4 and small cell lung carcinoma: Finally, the combination of anti‐PD‐L1 + anti‐CTLA‐4 + CT did not show advantages over other CIT strategies in improving survival, but still exhibited OS superiority over CT alone in ES‐SCLC patients without LM.